Incidence of side effects during the application of placebo and active therapy (Tobanum) in patients suffering from hypertension, angina pectoris and arrhythmia.
In a single blind clinical trial the effects of Tobanum (chloranolol), a beta-adrenergic receptor blocker, on 450 patients were examined. The side effects were detected by placebo control. Complaints were recorded on a questionnaire in the placebo period as well as in the active treatment period. Every fourth patient reported complaints in the placebo period and every third had a new complaint in the active period. Qualitative and quantitative analysis of the complaints indicated that Tobanum has mainly cardiorespiratory side effects judging from the beta-blocker characteristics. The study draws attention to the need for awareness of complaints in the placebo period for correct evaluation of side effects.
Török
E
E
Kósa
E
E
Szontagh
M
M
Juvancz
P
P
Eggenhofer
J
J
Borvendég
J
J
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D002493:Central Nervous System Diseases / Q000139:chemically induced; D002986:Clinical Trials as Topic; D003875:Drug Eruptions / Q000209:etiology; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000009:adverse effects* / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; C025725:tobanum